Curis Lifesciences buys 51% of Uninova to scale branded pharma in India and exports
Curis Lifesciences has acquired a 51% stake in Uninova Lifesciences, adding a roughly 50-product own-brand portfolio and distribution platform. The company plans further launches, targets over 100 products by year-end and is pursuing growth in Kenya and Nigeria.
What happened
Curis Lifesciences acquired a 51% stake in Uninova to expand India’s branded-pharma distribution and product portfolio, including injectables. It also targets
Key facts
- 51% stake acquired in Uninova Lifesciences
- Uninova has approximately 50 own-brand products
- Around 12 additional products planned
- Target of more than 100 products by year-end
- Six injectable products across four molecules launched
- Previous-year Uninova turnover: approximately INR 5.43 crore
- Current-year turnover target: approximately INR 7 crore
- Own-brand sales expected to rise from approximately INR 0.75 crore to INR 3 crore
- Kenya purchase orders: approximately INR 3 crore across three orders
- Kenya merchant-export sales expected to rise 30–40% year-on-year
- Seven Nigeria product dossiers accepted
- Nigeria annual sales potential estimated at INR 3–4 crore
Why this matters
Uninova gives Curis an immediately scalable branded-product and distribution asset while creating a platform for bolt-on launches and deeper expansion across African markets.
What to watch
- Confirmation that the portfolio reaches 100 products by year-end.
- Kenya order size, repeat purchase cadence and distributor expansion beyond initial shipments.
- Nigerian dossier approvals converting into marketed products and local distribution agreements.
- Disclosure of branded-sales mix, gross-margin improvement and integration costs.
- Growth in receivables, inventory days or debt that signals export working-capital pressure.
- Further acquisitions of brand portfolios, marketing companies or Africa-focused distributors.
- Launch or relaunch acquired Uninova brands through Curis-backed field sales and distributor channels.
- File additional dossiers and secure product registrations in Kenya, Nigeria and adjacent African markets.
- Expand the portfolio toward 100-plus products through new launches, line extensions and possible bolt-on acquisitions.
- Increase inventory, receivables financing and regulatory/commercial hiring to support export orders.
- Prioritize higher-margin chronic, specialty or differentiated formulations over commoditized acute generics.